<DOC>
	<DOCNO>NCT00627887</DOCNO>
	<brief_summary>The purpose study determine continuation electroconvulsive therapy ( ECT ) safe effective relapse prevention depression .</brief_summary>
	<brief_title>Randomised Controlled Trial Electroconvulsive Therapy ( ECT ) Relapse Prevention Depression</brief_title>
	<detailed_description>Randomized multicenter clinical trial two parallel group . Patients major depression ( unipolar bipolar ) , remit electroconvulsive therapy ( ECT ) eligible . All patient receive pharmacotherapy ( venlafaxine target dose 300mg/day , lithium target dose 0,5-0,8 mmol/L ) . The intervention continuation unilateral ECT weekly first 6 week thereafter every 2 week one year . Depressive relapse primary outcome measure .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<criteria>1 . MINIPLUS verify major depressive episode ( unipolar bipolar ) . 2 . ECT within last 3 week . 3 . Either Remission define MADRS &lt; 10 4 . Response define MADRS &lt; 15 combine patient assess CGII least much improve 1 . Schizophrenia Schizoaffective disorder 2 . Addiction Dependence 3 . Kidney disease contraindicate lithium treatment 4 . Vascular heart disease contraindicate venlafaxine treatment 5 . Uncontrolled Epilepsia 6 . Age less 18 7 . Pregnancy Lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Depressive Disorder , Major</keyword>
	<keyword>Electroconvulsive Therapy</keyword>
	<keyword>Lithium Carbonate</keyword>
	<keyword>venlafaxine</keyword>
</DOC>